Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$82.08

-0.75 (-0.91%)

, ZYME

Zymeworks

$10.53

0.07 (0.67%)

04:55
02/27/18
02/27
04:55
02/27/18
04:55

BTIG to hold a conference

Healthcare Conference: Therapeutics will be held in Snowbird, Utah on February 26-27.

AGIO

Agios Pharmaceuticals

$82.08

-0.75 (-0.91%)

ZYME

Zymeworks

$10.53

0.07 (0.67%)

KIDS

OrthoPediatrics

$17.71

-0.6 (-3.28%)

LMAT

LeMaitre

$35.66

-0.13 (-0.36%)

GMED

Globus Medical

$47.47

-0.44 (-0.92%)

BLUE

Bluebird Bio

$201.15

-4.9 (-2.38%)

CASC

Acquired by SGEN

$9.99

-0.01 (-0.10%)

DXCM

DexCom

$56.97

0.61 (1.08%)

HQY

HealthEquity

$54.99

2.485 (4.73%)

DYNT

Dynatronics

$2.70

-0.15 (-5.26%)

MYGN

Myriad Genetics

$33.34

0.2 (0.60%)

SIEN

Sientra

$9.94

0.38 (3.97%)

SHPG

Shire

$126.32

-0.76 (-0.60%)

NTLA

Intellia Therapeutics

$29.01

2.89 (11.06%)

NKTR

Nektar

$90.56

0.96 (1.07%)

NEO

NeoGenomics

$8.52

0.49 (6.10%)

MMSI

Merit Medical

$47.80

1.05 (2.25%)

CRY

CryoLife

$19.05

0.25 (1.33%)

CFMS

ConforMIS

$1.41

-0.01 (-0.70%)

VIVE

Viveve

$4.37

0.13 (3.07%)

PRTA

Prothena

$35.10

0.49 (1.42%)

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 08

    Mar

  • 11

    Mar

  • 13

    Mar

  • 23

    Mar

  • 25

    Mar

  • 04

    Apr

  • 03

    May

  • 21

    Aug

AGIO Agios Pharmaceuticals
$82.08

-0.75 (-0.91%)

02/15/18
RHCO
02/15/18
NO CHANGE
Target $101
RHCO
Buy
Agios Pharmaceuticals price target raised to $101 from $80 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Agios Pharmaceuticals to $101, citing increasing value of AG-348 that is expected to begin in Q2 of this year. The analyst also points to AG-270 trial starting in Q1 of this year and a perioperative "window" study of ivosidenib/AG-881 in glioma as potential catalysts. Suneja concludes that 4 Agios Pharmaceuticals is "making rapid progress on al fronts", keeping his Buy rating on the stock.
02/14/18
OPCO
02/14/18
DOWNGRADE
OPCO
Perform
Agios Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
02/14/18
OPCO
02/14/18
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Agios on valuation after Q4 results
Oppenheimer analyst Leah Rush Cann downgraded Agios Pharmaceuticals to Perform from Outperform following this morning's Q4 results. The analyst, who rescinded her price target, says that while the company's pipeline programs are moving forward, the shares trade inline with her valuation following the substantial rally over the previous 12 months. Cann adds Agios's recent capital raise resulted in approximately 17% dilution.
02/15/18
FBCO
02/15/18
NO CHANGE
Target $80
FBCO
Outperform
Agios Pharmaceuticals price target raised to $80 from $66 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Agios Pharmaceuticals to $80 from $66 as she sees upside opportunities in her valuation model related to newly diagnosed success in ivosidenib, PKD, AG-270 and DHODH. The analyst reiterates an Outperform rating on the shares.
ZYME Zymeworks
$10.53

0.07 (0.67%)

09/06/17
LEHM
09/06/17
DOWNGRADE
Target $8
LEHM
Underweight
Zymeworks assumed with an Underweight from Overweight at Barclays
Barclays analyst Gena Wang assumed coverage of Zymeworks and double downgraded the shares to Underweight from the firm's previous rating of Overweight. She cut her price target to $8 from $20. The analyst has low expectations for the company's lead asset HER2 dispecific antibody ZW25 in HER and high and medium expressed breast cancer.
05/24/17
SBSH
05/24/17
INITIATION
Target $18
SBSH
Buy
Zymeworks initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Zymeworks with a Buy rating and $18 price target. The analyst believes the company's platform and technology could open the door to a bigger piece of the breast cancer market.
05/24/17
05/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with an Overweight at Piper Jaffray. 2. Zymeworks (ZYME) initiated with a Buy at Citi. 3. Murphy Oil (MUR) initiated with a Buy at KLR Group. 4. Atlas Financial (AFH) initiated with an Outperform at JMP Securities. 5. Emerald Expositions Events (EEX) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/17
09/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. trivago (TRVG) downgraded to Neutral from Buy at BofA/Merrill with analyst Nat Schindler citing a surprise lowering of its 2017 revenue growth target to 40% from 50% and reduced adjusted EBITDA to down year-over-year. 2. Carrizo Oil & Gas (CRZO) downgraded to Neutral from Buy at Mizuho with analyst Timothy Rezvan saying Carrizo faces too many near-term headwinds and doesn't see Net Asset Value upside driving near-term stock outperformance. 3. Varian Medical (VAR) downgraded on valuation, macro concerns at BTIG with analyst Sean LAvin saying he downgraded the stock "mainly on valuation." However, he also believes that the company's results could be hurt by "instability in Korea and multiple hurricanes." 4. Zymeworks (ZYME) assumed with an Underweight from Overweight at Barclays with analyst Gena Wang saying she has low expectations for the company's lead asset HER2 dispecific antibody ZW25 in HER and high and medium expressed breast cancer. 5. Sealed Air (SEE) downgraded to Neutral from Buy at Citi with analyst Anthony Pettinari saying the company's annual guidance is at risk due to resin headwinds post Hurricane Harvey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
KIDS OrthoPediatrics
$17.71

-0.6 (-3.28%)

01/05/18
PIPR
01/05/18
NO CHANGE
Target $24
PIPR
Overweight
Piper says OrthoPediatrics' Q4 pre-announcement shows growth 'clicking along'
Piper Jaffray analyst Matt O'Brien noted that OrthoPediatrics pre-announced Q4 revenue that topped his expectations and the consensus view, which he points to as proof that the company's growth story keeps "clicking along." While acknowledging the company will face tough comps next year, he said he is confident the business will continue to accelerate as the company invests its IPO proceeds. O'Brien reiterates an Overweight rating and $24 price target on OrthoPediatrics shares.
11/06/17
11/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) was initiated with a Sector Perform at RBC Capital, a Market Perform at Raymond James and JMP Securities, and a Neutral at Goldman Sachs. 2. OrthoPediatrics (KIDS) was initiated with a Buy at Stifel and BTIG while being initiated with an Overweight at Piper Jaffray. 3. Rimini Street (RMNI) initiated with an Outperform at Cowen. 4. Rigel Pharmaceuticals (RIGL) assumed with a Buy at H.C. Wainwright. 5. Great Elm Capital (GECC) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/17
STFL
11/06/17
INITIATION
Target $23
STFL
Buy
OrthoPediatrics initiated with a Buy at Stifel
Stifel analyst Rick Wise started OrthoPediatrics Corp. with a Buy rating and $23 price target, stating that it offers the most comprehensive and expanding product portfolio to the "historically neglected" market of pediatric orthopedic implants and instruments. He projects OrthoPediatrics' portfolio will support a high-teens revenue CAGR through 2022.
11/06/17
BTIG
11/06/17
INITIATION
Target $24
BTIG
Buy
OrthoPediatrics initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman initiated OrthoPediatrics with a Buy rating and a $24 price target, saying the company's products address numerous market opportunities for pediatric patients' anatomical needs. The analyst notes that the company is a leading brand among pediatric orthopedic surgeons, and its business model is "scalable and defendable". Zimmerman ads that OrthoPediatrics could be a potential acquisition target for a larger orthopedic company.
LMAT LeMaitre
$35.66

-0.13 (-0.36%)

10/27/17
FANA
10/27/17
DOWNGRADE
FANA
Equal-Weight
LeMaitre downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Joseph Munda downgraded LeMaitre Vascular to Equal-Weight citing valuation following the company's Q3 results. The analyst believes the company's fundamentals remain attractive and keeps a $34 price target for the shares.
02/22/18
BRRR
02/22/18
NO CHANGE
BRRR
LeMaitre earnings, guidance solid, says Barrington
Barrington analyst Michael Petusky maintained a Market Perform rating on LeMaitre shares, saying while the company reported a solid Q4, exceeding the firm's estimate on the bottom line, increased its dividend 27.3%, and guided for a solid FY18, it remains difficult to gauge valuation, and Petusky would reconsider if the event of non-fundamental share weakness.
10/27/17
BNCH
10/27/17
DOWNGRADE
BNCH
Hold
LeMaitre downgraded to Hold from Buy at Benchmark
10/27/17
10/27/17
DOWNGRADE

Hold
LeMaitre downgraded to Hold on slowing growth at Benchmark
As previously reported, Benchmark analyst Raymond Myers downgraded LeMaitre (LMAT) to Hold from Buy noting that is growth has slowed from its prior "unsustainable" pace and he sees some operational challenges. In the wake of the "unexpected" mid-2016 support from Baxter's (BAX) competitive recall, he anticipates tougher 2017 comparisons, he tells investors.
GMED Globus Medical
$47.47

-0.44 (-0.92%)

01/10/18
WELS
01/10/18
NO CHANGE
Target $51
WELS
Outperform
Globus Medical price target raised to $51 from $46 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Globus Medical to $51 from $46 following the company's preliminary Q4 results and 2018 financial outlook, both of which exceeded expectations. The analyst reiterates an Outperform rating on the shares.
02/22/18
ADAM
02/22/18
NO CHANGE
Target $53
ADAM
Buy
Globus Medical price target raised to $53 from $47 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Globus Medical to $53 from $47 following solid Q4 results. The analyst cited continued share gains in the U.S. business, strong growth outside the U.S., and positive momentum in its Emerging Technologies segment. Rose reiterated his Buy rating on Globus Medical shares.
02/22/18
BTIG
02/22/18
NO CHANGE
Target $51
BTIG
Buy
Globus Medical price target raised to $51 from $45 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on Globus Medical to $51, saying the company's Q4 earnings highlighted the momentum from the recent robotics launch. Zimmerman believes that the company's ability to grow its market share will depend on product innovation and expanding its salesforce, which he believes can be achieved with the reinvestment of the gains from U.S. tax changes. The analyst also keeps his Buy rating on Globus Medical, stating that while the upside in the core U.S. spine market growth is limited, the company can outperform from new product launches.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
BLUE Bluebird Bio
$201.15

-4.9 (-2.38%)

01/25/18
LEER
01/25/18
DOWNGRADE
Target $194
LEER
Market Perform
Leerink downgrades bluebird bio with pipeline reaching fair value
Leerink analyst Michael Schmidt downgraded bluebird bio to Market Perform from Outperform while raising his price target for the shares to $194 from $162. The stock closed yesterday up $7.25 to $207.45. The company's clinical stage pipeline now is fairly valued while visibility into additional near-term sources of upside is limited, Schmidt tells investors in a research note. He notes the stock has rallied 390% since he initiated the name in February of 2016. The analyst thinks the $10.8BB market capitalization fairly values bluebird bio's pipeline. Schmidt expects the company to ultimately be acquired, but admits that it is difficult to predict if an acquisition will happen in the near term.
02/22/18
CANT
02/22/18
NO CHANGE
Target $122
CANT
Underweight
bluebird bio shares remain overvalued, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for bluebird bio to $122 while reiterating an Underweight rating on the name following the company's Q4 results. The analyst continues to view the shares as overvalued. He does not believe approval across the platform can support the current stock price.
01/25/18
01/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Discover (DFS) downgraded to In Line from Outperform at Evercore ISI. 2. BlackRock (BLK) downgraded to Neutral from Buy at Citi with analyst William Katz saying the "revaluation thesis" is now well understood. 3. bluebird bio (BLUE) downgraded to Market Perform from Outperform at Leerink with analyst Michael Schmidt saying the company's clinical stage pipeline now is fairly valued while visibility into additional near-term sources of upside is limited. 4. Jagged Peak Energy (JAG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Scott Hanold citing a tight frac service market in the Permian that lowers his projected growth outlook, saying the company is "more susceptible to frac service constraints due to its smaller scale and being a relatively newer entrant." 5. Varian Medical (VAR) downgraded to Sell from Neutral at Goldman Sachs with analyst Isaac Ro saying shares offer poor risk/reward versus MedTech peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/18
BERN
02/22/18
NO CHANGE
Target $211
BERN
Market Perform
bluebird bio price target raised to $211 from $153 at Bernstein
Bernstein analyst Vincent Chen raised his price target for bluebird to $211 from $153 following quarterly results and driven primarily by incorporation of a 30% premium for takeout potential. The analyst reiterates a Market Perform rating on the shares.
CASC Acquired by SGEN
$9.99

-0.01 (-0.10%)

02/07/18
HCWC
02/07/18
NO CHANGE
Target $77
HCWC
Buy
H.C. Wainwright ups Seattle Genetics target to $77 on tumor pipeline
Seattle Genetics' (SGEN) solid tumor pipeline is the "most interesting value driver" with three late-stage programs that could expand the company's footprint beyond hematology, H.C. Wainwright analyst Andrew Fein tells investors in a research note titled "Looking Ahead With a Solid Tumor Play." The analyst believes the recent acquisition of Cascadian Therapeutics (CASC) and the HER2+ breast cancer asset, tucatinib, further supports the view that Seattle Genetics is "throwing more weight behind the expansion/diversification from the hematologic malignancies territory into the solid tumor domain." Fein raised his price target for the shares to $77 from $75 and reiterates a Buy rating on the name.
01/31/18
PIPR
01/31/18
NO CHANGE
Target $55
PIPR
Neutral
Seattle Genetics acquisition adds late-stage cancer drug, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Seattle Genetics' (SGEN) "surprise" acquisition of Cascadian Therapeutics (CASC) adds a late-stage cancer drug and also expands the company beyond its antibody-drug conjugate focus. To pay for the deal, Seattle Genetics is aiming to raise $550M, Tenthoff tells investors in a research note. He keeps a Neutral rating on the shares with a $55 price target.
01/31/18
RAJA
01/31/18
DOWNGRADE
RAJA
Market Perform
Cascadian Therapeutics downgraded to Market Perform at Raymond James
Raymond James downgraded Cascadian Therapeutics (CASC) to Market Perform from Outperform after Seattle Genetics (SGEN) announced it has reached a deal to acquire Cascadian for $10 per share in cash.
01/31/18
RAJA
01/31/18
DOWNGRADE
RAJA
Market Perform
Raymond James sees no other bidders, downgrades Cascadian after deal
Raymond James analyst Reni Benjamin downgraded Cascadian Therapeutics (CASC) to Market Perform from Outperform after the company agreed to be acquired by Seattle Genetics (SGEN) for $10 per share. The acquisition is "great news" for Cascadian shareholders as it unlocks the risk-adjusted value of tucatinib immediately, Benjamin tells investors in a research note. He views the proposed acquisition as a "fair deal" and expects no competing bidders to emerge.
DXCM DexCom
$56.97

0.61 (1.08%)

01/30/18
PIPR
01/30/18
NO CHANGE
Target $60
PIPR
Overweight
Study shows superior outcomes for Dexcom over Abbott, says Piper Jaffray
Results of the I HART study that were published in the Diabetic Medicine journal showed superior outcomes for those on the Dexcom's (DXCM) G5 compared to Abbott's (ABT) Libre, Piper Jaffray analyst JP McKim tells investors in a research note. Specifically, G5 reduced time spent in hypoglycaemia both during the day and at night versus Libre that actually increased time, McKim adds. The analyst believes that while patients in the trial were ideal Dexcom candidates given their increased risk of hypoglycemia, the data can be used to differentiate the technology in the eyes of payers. He believes both G5 and Libre have a place in the system for different patient populations. The analyst keeps an Overweight rating on Dexcom with a $60 price target.
02/27/18
JPMS
02/27/18
NO CHANGE
JPMS
Abbott's strong Libre launch supports cautious Dexcom stance, says JPMorgan
Abbott's Libre launch is off to a strong start in the U.S. with more than 25,000 patients having started on the device since the launch in early December, JPMorgan analyst Michael Weinstein tells investors in a research note. It remains way too early, however, to say what percent of patients will stick with the device, the analyst adds. The Libre launch reinforces the analyst's cautious stance on shares of Dexcom (DXCM). He expects Dexcom's growth to slow over the course of the year and for 2019 to prove "much more challenging" than 2018. Weinstein has an Overweight rating on Abbott and Neutral rating on Dexcom.
02/12/18
OPCO
02/12/18
NO CHANGE
Target $67
OPCO
Outperform
Dexcom price target lowered to $67 from $72 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.
01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
02/26/18
PIPR
02/26/18
NO CHANGE
Target $60
PIPR
Overweight
Medtronic news incremental negative for Dexcom, says Piper Jaffray
Medtronic (MDT) this morning announced it received a new arm indication for its Guardian Sensor 3 which improves the accuracy of the sensor to an 8.7% MARD, likely leading to a non-adjunctive claim for standalone, Piper Jaffray analyst JP McKim tells investors in a research note. The news is an incremental negative for Dexcom (DXCM) shares as a path to non-adjunctive claim for Medtronic has become much clearer, McKim contends. He expects a stand-alone launch of Guardian Sensor 3 sometime in 2018. The analyst believes Dexcom carries more negative headline risk in the near term, but he expects the company to remain the market leader in continuous glucose monitors. As such, McKim thinks longer term investors should be buying the stock. He keeps an Overweight rating on Dexcom with a $60 price target. The stock in morning trading is down 12c to $56.24.
HQY HealthEquity
$54.99

2.485 (4.73%)

09/26/17
OPCO
09/26/17
NO CHANGE
OPCO
Graham-Cassidy health bill would be positive for HealthEquity, says Oppenheimer
Oppenheimer analyst Mohan Naidu notes that he does not know if the Graham-Cassidy health reform bill will go through. The analyst believes its passage would be a clear win for HealthEquity (HQY), as it would nearly double HSA contribution limits. On HMS Holdings (HMSY), however, passage likely hurts sentiment on possible slowdown in Medicaid spending and reshuffle in funding allocation but unlikely to impact numbers near-term, he contended.
02/08/18
CANT
02/08/18
NO CHANGE
Target $60
CANT
Overweight
HealthEquity selloff yesterday overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views the pullback yesterday in shares of HealthEquity as overdone. The analyst says the company's "light" fiscal 2019 revenue guidance is not concerning as he still expects 22.9% growth. He sees no fundamental reason for the share weakness and reiterates an Overweight rating on HealthEquity with a $60 price target.
01/04/18
SBSH
01/04/18
INITIATION
Target $69
SBSH
Buy
HealthEquity initiated with a Buy at Citi
Citi analyst Stephanie Davis started HealthEquity with a Buy rating and $69 price target. The analyst sees a "compelling entry point" following the recent pullback in shares.
03/31/17
03/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Market Perform at Wells Fargo. 2. Amazon.com (AMZN) was initiated with a Buy at Loop Capital while Alphabet (GOOG, GOOGL) was initiated with a Hold. 3. Dermira (DERM) initiated with a Buy at Mizuho. 4. TSYS (TSS) initiated with a Buy at Guggenheim. 5. HealthEquity (HQY) initiated with an Overweight at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DYNT Dynatronics
$2.70

-0.15 (-5.26%)

MYGN Myriad Genetics
$33.34

0.2 (0.60%)

11/10/17
JPMS
11/10/17
NO CHANGE
Target $19
JPMS
Underweight
JPMorgan continues to see downside risk in Myriad Genetics
After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.
12/11/17
PIPR
12/11/17
NO CHANGE
PIPR
Overweight
Piper says CMS coding edits could negatively impact Myriad Genetics
The Centers for Medicare and Medicaid Services made an edit to its procedure guidelines, essentially stating labs should use code 81162, instead of combining 81211 and 81213, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Myriad Genetics bills BRCA tests using the two codes. As such, the edit by CMS could have financial implications for the company as 81162 is paid 21% lower than the combined 81211/81213 rate, Quirk points out. He notes, however, that Myriad management states these coding edits were expected and already factored into guidance. Quirk believes the company's outlook for the second half of 2018 "appears low enough," but he notes that this is the first he's heard about the CMS change. He has a Neutral rating on Myriad with a $29 price target. The stock in morning trading is down 3% to $32.66.
01/29/18
GSCO
01/29/18
INITIATION
Target $32
GSCO
Sell
Myriad Genetics initiated with a Sell at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Myriad Genetics with a Sell and $32 price target citing "extended" valuation and excess optimism around GeneSight reimbursement.
11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
SIEN Sientra
$9.94

0.38 (3.97%)

02/21/18
LSCM
02/21/18
DOWNGRADE
Target $11
LSCM
Hold
Sientra downgraded to Hold from Buy at Lake Street
Lake Street analyst Brooks O'Neil downgraded Sientra to Hold and lowered his price target for the shares to $11 from $15. The company is "attempting to walk a fine line" with the at-the-market equity offering announced last night, O'Neil tells investors in a research note. The analyst does not sense there is a new delay related to securing FDA approval for silicone breast implant manufacturing with Vesta, but thinks near-term cash consumption, execution, and dilution risks may act as an overhang on the stock.
01/19/18
01/19/18
UPGRADE
Target $14

Buy
Sientra upgraded to Buy at Stifel
As previously reported, Stifel analyst Johnathan Block upgraded Sientra to Buy from Hold, stating that his September checks showed likely market share gains upon full resumption of manufacturing. Doctor feedback from miraDry users indicate that results appear efficacious and patient volumes are expected to increase, Block added. The analyst, who also pointed to easy year-ago comps in the second half for both of the company's businesses, set a $14 price target on Sientra shares. However, he did note that the upgrade may be coming before Sientra may end up raising additional capital in the near-term.
01/19/18
STFL
01/19/18
UPGRADE
STFL
Buy
Sientra upgraded to Buy from Hold at Stifel
09/13/17
WBLR
09/13/17
UPGRADE
WBLR
Outperform
Sientra upgraded to Outperform from Market Perform at William Blair
William Blair analyst Margaret Kaczor upgraded Sientra to Outperform saying the manufacturing approval is "just the tip of the story."
SHPG Shire
$126.32

-0.76 (-0.60%)

02/20/18
RHCO
02/20/18
NO CHANGE
Target $190
RHCO
Buy
Shire price target lowered to $190 from $260 at SunTrust
SunTrust analyst John Boris lowered his price target on Shire to $190, citing expectations of lower Factor VIII sales from higher Hemlibra risk along with higher costs associated with Covington manufacturing facility. The analyst keeps his Buy rating, saying the expected second-half of 2018 launch of Lanadelumab, as well as the strategic decision on the Neuroscience business, are potential upside catalysts for Shire.
02/20/18
JPMS
02/20/18
DOWNGRADE
Target $150
JPMS
Neutral
JPMorgan sees few catalysts for Shire, downgrades shares to Neutral
JPMorgan analyst James Gordon yesterday downgraded Shire to Neutral while lowering his price target for the shares to $150 from $200. The analyst sees few catalysts in 2018 and 2019 beyond a potential NeuroScience spinoff, which he does not see as creating fundamental value. Further, he believes the "Haemophilia overhang" will likely to weigh on Shire's Rare Disease business over the next two years.
02/22/18
BOFA
02/22/18
NO CHANGE
BOFA
Buy
Shire post results weakness overdone, says BofA/Merrill
BofA/Merrill analyst Graham Parry believes Shire post results weakness is overdone and says shares remain undervalued. The analyst argued that cons EPS cuts are already priced in, and reiterates a Buy rating on the shares.
02/20/18
02/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Sell from Neutral at Citi with analyst Mark May saying the recent flagship app redesign could produce positive long-term benefits, but the "significant jump" in negative app reviews since the redesign was pushed out a few weeks could result in a decline in users and user engagement, and could negatively impact financial results. 2. Wingstop (WING) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing the recent surge in the shares, which has left less room for upside on a near-term basis. 3. Northrop Grumman (NOC) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Noah Poponak citing valuation. 4. JPMorgan sees few catalysts for Shire (SHPG), downgrades shares to Neutral with analyst James Gordon saying he sees few catalysts in 2018 and 2019 beyond a potential NeuroScience spinoff, which he does not see as creating fundamental value. 5. Teck Resources (TECK) downgraded to Neutral from Outperform at Macquarie with analyst Matt Murphy citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NTLA Intellia Therapeutics
$29.01

2.89 (11.06%)

01/09/18
JEFF
01/09/18
NO CHANGE
Target $42
JEFF
Buy
Intellia selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft views yesterday's selloff in shares of Intellia Therapeutics as a buying opportunity. The analyst calls the pullback "excessive" based on his analysis of Friday's publication related to CRISPR/Cas9 that raised safety/efficacy questions pertaining to the genome-editing technology. The analyst views the data in the publication as early and limited. He keeps a Buy rating on Intellia with a $42 price target.
01/08/18
LEER
01/08/18
NO CHANGE
LEER
Outperform
Intellia Therapeutics selloff on bioRxiv article overdone, says Leerink
Leerink analyst Joseph Schwartz attributes today's selloff in shares of Intellia Therapeutics to concerns raised about the genome editing approach using CRISPR/Cas9 in a paper published by bioRxiv. However, he points out that the articles on that site are not peer-reviewed and he questions the quality of the data. The analyst, who also contends the humoral response issue raised in the repot is unlikely to be material for Intellia, believes today's selloff is overdone and reiterates an Outperform rating on Intellia shares, which are down about 15% in early afternoon trading.
10/31/17
JEFF
10/31/17
NO CHANGE
Target $42
JEFF
Buy
Intellia Therapeutics price target raised to $42 from $36 at Jefferies
10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
NKTR Nektar
$90.56

0.96 (1.07%)

02/22/18
JEFF
02/22/18
DOWNGRADE
Target $66
JEFF
Hold
Jefferies downgrades Alkermes to Hold after 'deep dive' on cancer drug
Jefferies analyst Biren Amin downgraded Alkermes (ALKS) to Hold from Buy with an unchanged price target of $66. The shares closed yesterday down $1.56 to $63.19. The stock is fairly valued and price in "significant value" for the late-stage pipeline, Amin tells investors in a research note. He believes that Vivitrol and Aristada continue to experience "modest growth," which is unlikely to drive Alkermes shares higher. Further, following a "deep dive" on immuno-oncology candidate ALKS 4230, Amin believes preclinical data suggest the drug may be weaker on efficacy than Nektar Therapeutics' (NKTR) interleukin-2 receptor NKTR-214. ALKS 4230 is "inherently different" from NKTR-214 based on cross comparison of preclinical data, Amin writes in a research note partially titled "Closer Look at IL-2 Science Suggests Not All IL-2s Are The Same."
02/16/18
SBSH
02/16/18
UPGRADE
Target $14
SBSH
Buy
Calithera Biosciences upgraded to Buy from Neutral at Citi
Citi analyst Robyn Karnauskas upgraded Calithera Biosciences (CALA) to Buy with an unchanged price target of $14. The stock has been under pressure after Phase 1 data from the CB-839/PD-1 combo, presumably due to comparison to Nektar Therapeutics' (NKTR) combo data, Karnauskas tells investors in a research note. She believes this is an unfair comparison, as Calithera and Nektar are targeting different patient populations, and the drugs have different mechanisms. The analyst views Calithera as underappreciated with the stock trading above cash with only $2 per share for the pipeline.
02/20/18
JEFF
02/20/18
INITIATION
Target $61
JEFF
Buy
Armo BioSciences initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Armo BioSciences (ARMO) with a Buy rating and $61 price target. The analyst thinks the shares will trade on potential for AM0010, an IL-10 cytokine. The data in non-small-cell lung carcinoma show "encouraging signals" and the pancreatic cancer data suggest better activity than chemo alone, Amin tells investors in a research note. He notes cytokines have recently garnered interest after Nektar Therapeutics (NKTR) inked a partnership with Bristol-Myers (BMY) for a $1.8B upfront.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.
NEO NeoGenomics
$8.52

0.49 (6.10%)

11/30/17
GABE
11/30/17
NO CHANGE
GABE
Buy
NeoGenomics named a best idea for 2018 at Gabelli
Gabelli analyst Sara Wojda named NeoGenomics a best idea for 2018 citing double-digit volume growth combined with double-digit reduction in cost per test, contined share gains in the core clinical services division, and expectations for stabilization in pricing for FISH tests. Wojda rates NeoGenomics a Buy with a $12 PMV.
04/26/17
CANT
04/26/17
NO CHANGE
Target $11
CANT
Overweight
NeoGenomics shares 'oversold' on lowered 2017 guidance, says Cantor
Cantor analyst Bryan Brokmeier reiterates an Overweight rating and a $11 price target on NeoGenomics following mixed Q1 results. The analyst notes that the stock is down after the company revised its 2017 outlook, but he believes shares are oversold. NeoGenomics has now completed its transition period, which had more of a near-term impact on the business than anticipated, he argues, adding that the distractions are behind them and the sales force can now focus on driving new business, including a pipeline of new customers, growing existing accounts, and cross-selling into 100 Clarient IHC-only accounts.
09/11/17
BTIG
09/11/17
DOWNGRADE
BTIG
Neutral
NeoGenomics downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded NeoGenomics to Neutral saying shares are near his $11 price target and sees risk to Q3 revenues given exposure to Texas and Florida, and lack of near-term catalysts.
10/26/17
JANY
10/26/17
NO CHANGE
JANY
Buy
NeoGenomics should be bought on post-earnings weakness, says Janney Capital
Janney Capital analyst Paul Knight believes NeoGenomics can meet and beat estimates now that guidance has been lowered and he recommends buying the shares on any post-earnings weakness. He also noted that the company has already opened its' Switzerland laboratory, ahead of its guidance for a November opening. Knight keeps a Buy rating on NeoGenomics shares.
MMSI Merit Medical
$47.80

1.05 (2.25%)

07/27/17
CHLM
07/27/17
NO CHANGE
Target $50
CHLM
Buy
Merit Medical price target raised to $50 from $42 at Craig-Hallum
Craig-Hallum analyst Charles Haff raised his price target for Merit Medical to $50 from $42 based upon "strong momentum" in virtually every revenue segment and operating leverage that continues to surprise to the upside. The analyst reiterates a Buy rating on the shares.
11/30/17
WELS
11/30/17
NO CHANGE
Target $51
WELS
Outperform
Merit Medical price target raised to $51 from $46 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Merit Medical (MMSI) to $51 from $46 to reflect MMSI's recently announced purchase agreement to acquire select Becton Dickinson (BDX) assets. The analyst reiterates an Outperform rating on Merit Medical's shares.
08/28/17
08/28/17
DOWNGRADE
Target $44

Outperform
Merit Medical downgraded to Outperform due to valuation at Raymond James
As previously reported, Raymond James downgraded Merit Medical to Outperform from Strong Buy with a $44 price target citing relative valuation.
08/28/17
RAJA
08/28/17
DOWNGRADE
RAJA
Outperform
Merit Medical downgraded to Outperform from Strong Buy at Raymond James
CRY CryoLife
$19.05

0.25 (1.33%)

07/26/17
ADAM
07/26/17
NO CHANGE
Target $25
ADAM
Buy
CryoLife foundation suggests opportunity for growth, says Canaccord
Canaccord analyst Jason Mills recommended investors build positions in CryoLife on the heels of solid Q2 results. The analyst noted its better than expected top and bottom line results and said its strong foundation portends a huge opportunity for growth via both its internal pipeline and M&A. Mills reiterated his Buy rating and raised his price target to $25 from $23.50 on CryoLife shares.
10/11/17
ADAM
10/11/17
NO CHANGE
Target $25
ADAM
Buy
CryoLife M&A to improve both top and bottom line, says Canaccord
Canaccord analyst Jason Mills said he favors CryoLife's bold move to augment the scale of its business and vastly improve its long-term growth prospects with its acquisition of JOTEC. The company focuses on the treatment of aortic disease, which will help diversify CryoLife's revenue streams while providing it access to the very large global stent graft market with differentiated technology, said Mills, who reiterated his Buy rating and maintained his $25 price target on CryoLife.
10/11/17
LSCM
10/11/17
NO CHANGE
Target $26
LSCM
Buy
CryoLife price target raised to $26 from $23.50 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for CryoLife to $26 after the company announced the acquisition of JOTEC AG, a Germany based privately-held developer of technologically differentiated endovascular stent grafts. The deal expands CryoLife's addressable market and accelerates growth, O'Neil tells investors in a research note. The analyst affirms a Buy rating on the shares.
10/12/17
ADAM
10/12/17
NO CHANGE
Target $25
ADAM
Buy
CryoLife weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the selloff in CryoLife shares following its conference call about its acquisition of JOTEC is overdone. The analyst remains bullish about its prospects and sees several merits to the deal. He said it improves CryoLife's long-term growth prospects and margin profile. Mills reiterated his Buy rating and $25 price target on CryoLife shares.
CFMS ConforMIS
$1.41

-0.01 (-0.70%)

01/02/18
JPMS
01/02/18
DOWNGRADE
JPMS
Underweight
ConforMIS downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein downgraded ConforMIS to Underweight without a price target. The analyst finds it "tough" to recommend owning the stock in 2018 given the company's cash burn, limited sales growth and the potential for additional financing at some point in the next 12 months.
12/20/17
12/20/17
UPGRADE
Target $4

Buy
ConforMIS upgraded to Buy at BTIG
As previously reported, BTIG analyst Ryan Zimmerman upgraded ConforMIS to Buy from Neutral, with a $4 price target, saying that while it still needs to improve production times, increase margins, and grow faster, at this valuation the risk/reward is favorable. Further, the analyst believes the strategies management has undertaken over the previous year could begin to bear fruit in FY18 and any return to growth will begin to lift shares.
12/20/17
BTIG
12/20/17
UPGRADE
BTIG
Buy
ConforMIS upgraded to Buy from Neutral at BTIG
02/21/18
COWN
02/21/18
INITIATION
Target $4
COWN
Outperform
ConforMIS initiated with an Outperform at Cowen
Cowen analyst Josh Jennings initiated ConforMIS with an Outperform and $4 price target telling investors its custom joint replacement technology is underappreciated. Orthopedic surgeon consultants have provided outstanding feedback detailing their own clinical experience with the iTotal platform and reporting meaningfully positive acute outcomes and patient satisfaction rates, the analyst wrote. Jennings expects expects accelerating 2018 growth and sustainable 2019 revenue growth with renewed momentum in the core knee franchise and iHip contributions.
VIVE Viveve
$4.37

0.13 (3.07%)

11/16/17
MZHO
11/16/17
INITIATION
Target $10
MZHO
Buy
Viveve initiated with a Buy at Mizuho
Mizuho initiated Viveve with a Buy and $10 price target.
01/05/18
NORL
01/05/18
INITIATION
Target $8
NORL
Outperform
Viveve initiated with an Outperform at Northland
Northland initiated Viveve with an Outperform and $8 price target.
02/22/18
EAMC
02/22/18
INITIATION
Target $10
EAMC
Viveve initiated with a Buy at Empire
Empire analyst Cathy Reese initiated Viveve with a Buy and $10 price target
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PRTA Prothena
$35.10

0.49 (1.42%)

02/05/18
NOMU
02/05/18
NO CHANGE
Target $87
NOMU
Buy
Prothena selloff on CMO resignation brings entry point, says Nomura Instinet
Nomura Instinet analyst Christopher Marai recommends using the weakness in shares of Prothena following the resignation of Chief Medical Officer Sarah Noonberg as a buying opportunity. The analyst keeps a Buy rating on the shares with an $87 price target.
02/05/18
CANT
02/05/18
NO CHANGE
Target $65
CANT
Overweight
Prothena data release could assuage concerns, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner cautions against "over-interpreting" the resignation of Prothena's Chief Medical Officer given the lack of details. The release of top-line data from the Phase 2b Pronto study has the ability to "clear the air" and assuage investor concerns, Tanner tells investors in a research note titled "PRONTO Trial Data Could Go A Long Way Toward Disproving A Negative." The analyst keeps an Overweight rating on the shares with a $65 price target.
12/21/17
CANT
12/21/17
NO CHANGE
Target $65
CANT
Overweight
Prothena price target lowered to $65 from $80 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Prothena to $65 after the company guided to the last event in the VITAL Phase 3 study likely occurring in the second half of 2019 versus the latter part of 2018 as previously expected. The analyst, however, believes the delay does little to change the long-term investment thesis. He keeps an Overweight rating on Prothena.
11/20/17
11/20/17
DOWNGRADE
Target $55

Neutral
Prothena downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Prothena to Neutral from Outperform as it is not clear to him that the one-year delay in VITAL unblinding to 2H19 could be due solely to NEOD001 benefit. With his Prothena valuation based almost entirely on NEOD001 success, the analyst sees risk/reward as now skewed to downside. Nierengarten also lowered his price target on the shares to $55 from $75.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.49

-0.775 (-1.71%)

12:44
07/15/18
07/15
12:44
07/15/18
12:44
Periodicals
Twitter suspends accounts linked to Russians indicted by Mueller, Reuters says »

Twitter has suspended two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 27

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
07/15/18
07/15
12:29
07/15/18
12:29
Periodicals
Trump says he will run for reelection, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:22
07/15/18
07/15
12:22
07/15/18
12:22
Periodicals
Airbus in talks for repeat Viva Aerobus jet order, Reuters says »

Airbus is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$350.81

4.79 (1.38%)

12:19
07/15/18
07/15
12:19
07/15/18
12:19
Periodicals
Boeing concerned about tariff talk, Reuters reports »

Boeing is concerned about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:17
07/15/18
07/15
12:17
07/15/18
12:17
Periodicals
President Trump calls EU a 'foe' on trade, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$203.32

1.29 (0.64%)

12:14
07/15/18
07/15
12:14
07/15/18
12:14
Hot Stocks
L3 Technologies appoints new SVP, Chief Global Business Development Officer »

L3 Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

0.43 (0.21%)

, TWTR

Twitter

$44.49

-0.775 (-1.71%)

13:27
07/14/18
07/14
13:27
07/14/18
13:27
Periodicals
Facebook, Alphabet to testify at U.S. House hearing, Reuters reports »

The U.S. House Judiciary…

FB

Facebook

$207.33

0.43 (0.21%)

TWTR

Twitter

$44.49

-0.775 (-1.71%)

GOOG

Alphabet

$1,188.81

4.94 (0.42%)

GOOGL

Alphabet Class A

$1,204.34

2.43 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

AAPL

Apple

$191.32

0.19 (0.10%)

, T

AT&T

$31.66

-0.56 (-1.74%)

13:06
07/14/18
07/14
13:06
07/14/18
13:06
Periodicals
Apple's next iPhone may be debut of eSIM, Barron's says »

Apple's (AAPL) next…

AAPL

Apple

$191.32

0.19 (0.10%)

T

AT&T

$31.66

-0.56 (-1.74%)

VZ

Verizon

$51.41

0.17 (0.33%)

S

Sprint

$5.66

(0.00%)

TMUS

T-Mobile

$61.68

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

AEP

American Electric

$70.37

-0.02 (-0.03%)

, NEE

NextEra Energy

$169.60

1.06 (0.63%)

12:57
07/14/18
07/14
12:57
07/14/18
12:57
Periodicals
Utility stocks worth a second look, Barron's says »

Utility stocks like…

AEP

American Electric

$70.37

-0.02 (-0.03%)

NEE

NextEra Energy

$169.60

1.06 (0.63%)

XEL

Xcel Energy

$46.26

-0.09 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

, CA

CA Technologies

$44.07

-0.08 (-0.18%)

12:50
07/14/18
07/14
12:50
07/14/18
12:50
Periodicals
Broadcom testing investors' faith, Barron's says »

For a while, shareholders…

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

CA

CA Technologies

$44.07

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16
Periodicals
Ackman might be making a comeback, Barron's says »

Bill Ackman's…

VRX

Valeant

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

ARNC

Arconic

$17.39

0.08 (0.46%)

, APO

Apollo Global

$36.13

0.26 (0.72%)

08:41
07/14/18
07/14
08:41
07/14/18
08:41
Periodicals
Apollo, other PE firms express interest in Arconic, WSJ reports »

Arconic (ARNC) has…

ARNC

Arconic

$17.39

0.08 (0.46%)

APO

Apollo Global

$36.13

0.26 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

XYL

Xylem

$68.55

0.485 (0.71%)

, AQUA

Evoqua Water

$20.71

(0.00%)

04:55
07/14/18
07/14
04:55
07/14/18
04:55
Conference/Events
RBC Capital to hold a field trip »

Asia Water Sector Field…

XYL

Xylem

$68.55

0.485 (0.71%)

AQUA

Evoqua Water

$20.71

(0.00%)

DHR

Danaher

$99.25

-0.4 (-0.40%)

PNR

Pentair

$43.53

0.67 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 07

    Aug

HJLI

Hancock Jaffe Laboratories

$3.20

-0.025 (-0.78%)

18:20
07/13/18
07/13
18:20
07/13/18
18:20
Hot Stocks
Hancock Jaffe Laboratories names Bob Rankin as CFO, effective July 16 »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CKH

Seacor

$53.63

0.69 (1.30%)

, LPG

Dorian LPG

$7.92

0.115 (1.47%)

18:16
07/13/18
07/13
18:16
07/13/18
18:16
Hot Stocks
Seacor favors combination of Dorian LPG and BW LPG Limited »

Seacor (CKH) announced…

CKH

Seacor

$53.63

0.69 (1.30%)

LPG

Dorian LPG

$7.92

0.115 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:53
07/13/18
07/13
17:53
07/13/18
17:53
Hot Stocks
Senator Rubio says ZTE 'should be put out of business' »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:26
07/13/18
07/13
17:26
07/13/18
17:26
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:25
07/13/18
07/13
17:25
07/13/18
17:25
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$7.49

0.09 (1.22%)

17:24
07/13/18
07/13
17:24
07/13/18
17:24
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

, XLU

Utilities SPDR

$52.56

0.04 (0.08%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
General news
Week ending ETF Scorecard: Industrials rebound into lead, Utilities lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

XLU

Utilities SPDR

$52.56

0.04 (0.08%)

IYR

DJ US Real Estate Index Fund

$81.37

-0.19 (-0.23%)

XLP

Consumer Staples Sector SPDR

$52.73

0.32 (0.61%)

XLY

Consumer Discretionary Sector SPDR

$112.62

0.27 (0.24%)

XLB

S&P Select Materials SPDR

$58.59

-0.02 (-0.03%)

XLF

Financial Select Sector

$26.96

-0.13 (-0.48%)

XLV

Health Care Select Sector SPDR

$87.44

0.18 (0.21%)

XLK

Technology Select Sector SPDR

$72.56

-0.07 (-0.10%)

XLI

Industrial Select Sector SPDR

$73.77

0.43 (0.59%)

GLD

SPDR Gold Trust

$117.60

-0.515 (-0.44%)

SLV

iShares Silver Trust

$14.88

-0.13 (-0.87%)

USO

United States Oil Fund

$14.47

0.085 (0.59%)

UNG

United States Natural Gas Fund

$22.40

-0.3 (-1.32%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.60

0.165 (0.16%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

0.025 (0.03%)

IWD

iShares Russell 1000 Value

$123.04

-0.07 (-0.06%)

IWF

iShares Russell 1000 Growth

$149.33

0.33 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$1.04

-0.015 (-1.42%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
Hot Stocks
CEL-SCI receives noncompliance letter from NYSE »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$53.47

-0.18 (-0.34%)

17:13
07/13/18
07/13
17:13
07/13/18
17:13
Hot Stocks
Yankees suspend relationship with Papa John's »

The New York Yankees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NCNA

NuCana

$24.00

-0.01 (-0.04%)

17:08
07/13/18
07/13
17:08
07/13/18
17:08
Hot Stocks
Breaking Hot Stocks news story on NuCana »

Christopher B. Wood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.